580 related articles for article (PubMed ID: 32506725)
1. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.
Ulrich H; Pillat MM; Tárnok A
Cytometry A; 2020 Jul; 97(7):662-667. PubMed ID: 32506725
[TBL] [Abstract][Full Text] [Related]
2. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent enhancement of coronavirus.
Wen J; Cheng Y; Ling R; Dai Y; Huang B; Huang W; Zhang S; Jiang Y
Int J Infect Dis; 2020 Nov; 100():483-489. PubMed ID: 32920233
[TBL] [Abstract][Full Text] [Related]
4. The role of IgG Fc receptors in antibody-dependent enhancement.
Bournazos S; Gupta A; Ravetch JV
Nat Rev Immunol; 2020 Oct; 20(10):633-643. PubMed ID: 32782358
[TBL] [Abstract][Full Text] [Related]
5. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.
Fierz W; Walz B
Front Immunol; 2020; 11():1120. PubMed ID: 32582200
[TBL] [Abstract][Full Text] [Related]
6. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.
Zhang YY; Li BR; Ning BT
Front Immunol; 2020; 11():2033. PubMed ID: 32922406
[TBL] [Abstract][Full Text] [Related]
7. Covid-19 and dengue: Double punches for dengue-endemic countries in Asia.
Harapan H; Ryan M; Yohan B; Abidin RS; Nainu F; Rakib A; Jahan I; Emran TB; Ullah I; Panta K; Dhama K; Sasmono RT
Rev Med Virol; 2021 Mar; 31(2):e2161. PubMed ID: 32946149
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
[TBL] [Abstract][Full Text] [Related]
9. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent enhancement (ADE) of SARS-CoV-2 in patients exposed to MERS-CoV and SARS-CoV-2 antigens.
Thomas S; Smatti MK; Alsulaiti H; Zedan HT; Eid AH; Hssain AA; Abu Raddad LJ; Gentilcore G; Ouhtit A; Althani AA; Nasrallah GK; Grivel JC; Yassine HM
J Med Virol; 2024 May; 96(5):e29628. PubMed ID: 38682568
[TBL] [Abstract][Full Text] [Related]
11. Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases.
Rossi GA; Sacco O; Mancino E; Cristiani L; Midulla F
Infection; 2020 Oct; 48(5):665-669. PubMed ID: 32737833
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
[TBL] [Abstract][Full Text] [Related]
13. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?
Negro F
Swiss Med Wkly; 2020 Apr; 150():w20249. PubMed ID: 32298458
[No Abstract] [Full Text] [Related]
14. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
Lee WS; Wheatley AK; Kent SJ; DeKosky BJ
Nat Microbiol; 2020 Oct; 5(10):1185-1191. PubMed ID: 32908214
[TBL] [Abstract][Full Text] [Related]
16. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
17. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP
Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
Wang SF; Tseng SP; Yen CH; Yang JY; Tsao CH; Shen CW; Chen KH; Liu FT; Liu WT; Chen YM; Huang JC
Biochem Biophys Res Commun; 2014 Aug; 451(2):208-14. PubMed ID: 25073113
[TBL] [Abstract][Full Text] [Related]
19. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
İnandıklıoğlu N; Akkoc T
Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
[TBL] [Abstract][Full Text] [Related]
20. [Strategies for vaccine development of COVID-19].
Yang L; Tian D; Liu W
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):593-604. PubMed ID: 32347054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
